[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100144812":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":35,"centralContacts":43,"locations":44,"responsibleParty":57,"collaborators":43,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":43,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":43,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":80,"whyStopped":81,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Universitätsklinikum Hamburg-Eppendorf","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"female","EXPERIMENTAL","The healthy female volunteers receive furosemide and aminohippurate sodium \"PAH\" as single dose randomised on day 1 or day 2.",[13,14],"Drug: Furosemide","Drug: aminohippurate sodium",{"label":16,"type":10,"description":17,"interventionNames":18},"male","The healthy male volunteers receive furosemide and aminohippurate sodium \"PAH\" as single dose randomised on day 1 or day 2",[13,14],[20,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Furosemide","Injection, 40 mg, single dose over 5 min",[9,16],[26,27],"ATC code: C03CA01","Product name: Lasix 40 mg Injektionslösung",{"type":21,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"aminohippurate sodium","Injection, 500 mg, single dose over 5 min",[9,16],[33,34],"ATC code: V04CH30,","Product name: Aminohipppurate Sodium \"PAH\"",[36,40],{"name":37,"affiliation":38,"role":39},"Thomas Eschenhagen, Prof.Dr.med.","Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg GERMANY","STUDY_DIRECTOR",{"name":41,"affiliation":38,"role":42},"Ulrike Werner, PD Dr.","PRINCIPAL_INVESTIGATOR",null,[45],{"facility":46,"status":43,"city":47,"state":43,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":43},"Clinical Trial Center North","Hamburg","20246","Germany","DE",{"type":52,"coordinates":53},"Point",[54,55],9.99302,53.55073,{"lat":55,"lon":54},{"type":58,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100144812","phase-4-investigation-of-gender-specificity-of-the-effects-of-furosemide-in-healthy-female-and-male-volunteers-100144812",false,"NCT01156220","Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers","Inclusion Criteria:\n\n* Healthy volunteer for medical history and physical examination findings\n* 18 years, \\\u003C40 years\n* Written informed consent is given\n* No clinically relevant changes in laboratory parameters\n* Inconspicuous current ECG\n* taking medication under a different drug trial within the last 30 days\n\nExclusion Criteria:\n\n* concomitant medication at study days or a week before\n* allergies or known hypersensitivity reactions to furosemide or aminohippurate sodium\n* decreased creatinine clearance by Cockcroft-Gault (\\\u003C100 ml \u002F min)\n* current drug abuses\n* opiate addiction within the last 10 years\n* smoking within the last year\n* pregnancy and 6 months postpartum, lactation\n* deprivation of legal capacity\n* Cooperation inability",true,"ALL","18 Years","39 Years",{"count":70,"type":71},0,"ACTUAL","INTERVENTIONAL",[74],"PHASE4","In this study the gender specificity of the effects of furosemide in female and male volunteers will be investigated. The main objective is gender-specific comparison of the pharmacokinetic parameters of furosemide in relation to the effect of furosemide (urinary excretion). Secondary objectives are the gender-specific comparison of renal and systemic PAH clearance with the clearance of furosemide and the influence of various genetic polymorphisms on the variability of furosemide pharmacokinetics.",[77],"Healthy Male and Female Volunteers",[79],"gender, diuretics, furosemide, aminohippuric acid","WITHDRAWN","Study was never implemented.","2022-06-29",{"date":84,"type":71},"2022-07-01",{"date":86,"type":87},"2012-01","ESTIMATED",{"date":89,"type":87},"2012-06",{"name":5,"class":6},1]